Author: Savarese, Gianluigi; Benson, Lina; Sundström, Johan; Lund, Lars H.
Title: Association between renin–angiotensin–aldosterone system inhibitor use and COVIDâ€19 hospitalization and death: a 1.4 million patient nationwide registry analysis Cord-id: g32bpgtx Document date: 2020_12_7
ID: g32bpgtx
Snippet: AIMS: Renin–angiotensin–aldosterone system inhibitors (RAASi) improve outcomes in cardiorenal disease but concerns have been raised over increased risk of incident hospitalization and death from coronavirus disease 2019 (COVIDâ€19). We investigated the association between use of angiotensinâ€converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs) or mineralocorticoid receptor antagonists (MRAs) and COVIDâ€19 hospitalization/death in a large nationwide population. METHODS
Document: AIMS: Renin–angiotensin–aldosterone system inhibitors (RAASi) improve outcomes in cardiorenal disease but concerns have been raised over increased risk of incident hospitalization and death from coronavirus disease 2019 (COVIDâ€19). We investigated the association between use of angiotensinâ€converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs) or mineralocorticoid receptor antagonists (MRAs) and COVIDâ€19 hospitalization/death in a large nationwide population. METHODS AND RESULTS: Patients with hypertension, heart failure, diabetes, kidney disease, or ischaemic heart disease registered in the Swedish National Patient Registry until 1 February 2020 were included and followed until 31 May 2020. COVIDâ€19 cases were defined based on hospitalization/death for COVIDâ€19. Multivariable logistic and Cox regressions were fitted to investigate the association between ACEi/ARB and MRA and risk of hospitalization/death for COVIDâ€19 in the overall population, and of allâ€cause mortality in COVIDâ€19 cases. We performed consistency analysis to quantify the impact of potential unmeasured confounding. Of 1 387 746 patients (60% receiving ACEi/ARB and 5.8% MRA), 7146 (0.51%) had incident hospitalization/death from COVIDâ€19. After adjustment for 45 variables, ACEi/ARB use was associated with a reduced risk of hospitalization/death for COVIDâ€19 (odds ratio 0.86, 95% confidence interval 0.81–0.91) in the overall population, and with reduced mortality in COVIDâ€19 cases (hazard ratio 0.89, 95% confidence interval 0.82–0.96). MRA use was not associated with risk of any outcome. Consistency analysis showed that unmeasured confounding would need to be large for there to be harmful signals associated with RAASi use. CONCLUSIONS: In a 1.4 million nationwide cohort, use of RAASi was not associated with increased risk of hospitalization for or death from COVIDâ€19.
Search related documents:
Co phrase search for related documents- acei arb effect and lung injury: 1
- acei arb significant association and logistic regression: 1, 2
- acei arb treatment and acute lung injury: 1
- acei arb treatment and logistic regression: 1, 2, 3, 4, 5
- acei arb treatment and lung injury: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date